Understanding malar rash

Malar rash, often referred to as a butterfly rash, is a distinctive facial presentation observed in various disorders. It manifests as an erythematous rash, either flat or raised, spanning the bridge of the nose and cheeks while typically sparing the nasolabial folds. This rash can be transient or progress to involve more facial areas. Predominantly associated with systemic lupus erythematosus (SLE), the malar rash is a diagnostic criterion for SLE according to the American College of Rheumatology. It is also seen in other forms of lupus, including discoid lupus and subacute cutaneous lupus. Differential diagnoses include cellulitis, rosacea, erysipelas, dermatomyositis, and pellagra. Effective management begins with sun protection, encompassing the use of appropriate clothing, sunscreens, and behavioral modifications. The underlying disease must also be treated accordingly.

Malar rash is linked to several conditions. The prevalence of these conditions varies. Rosacea affects about 5.46% globally, especially among fair-skinned Caucasians. SLE has an estimated prevalence of 1.5 million cases in the U.S., with the highest prevalence in North America. Dermatomyositis has an incidence of 9.63 cases per million people.

Diagnosing malar rash requires a comprehensive clinical history and physical examination. Laboratory tests, including complete blood counts and specific markers like ANA for SLE, are essential. For dermatomyositis, skin biopsies and regular evaluations of muscle enzymes are critical. Management of malar rash is condition-specific. Antibiotics are the mainstay for cellulitis and erysipelas. SLE and dermatomyositis treatments include sun protection, corticosteroids, and immunosuppressants. Rosacea treatment focuses on topical agents and antibiotics, while pellagra is managed with oral niacin.